A postmarketing study of relative abuse liability of hypnotic sedative drugs
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Aims To demonstrate the utility of postmarketing studies using in‐treatment drug and alcohol abusers as informants for assessing the relative abuse liability of sedative–hypnotic drugs. Design A survey was conducted that ascertained exposure to a variety of drugs with hypnotic/sedative properties and elicited subjective evaluations indicative of abuse liability. Methods Complete data were obtained from 297 admissions (78% male) to three addiction treatment sites in the United Kingdom. Subjects were asked 15 questions about 12 different drugs, including five benzodiazepines, three antidepressants, two non‐benzodiazepine hypnotics and two antihistamines (plus one fictitious drug). Three of the benzodiazepines (diazepam, nitrazipam, temazepam) emerged as having substantially more abuse liability than any of the other drugs tested, as revealed by higher scores on abuse liability items (purchased on street, taken to get high, like drug, potential for addiction to drug). The antihistamines (chlorpheniramine, diphenhydramine) had lowest abuse liability profiles, while the antidepressants (amitriptyline, fluoxetine, trazadone) and non‐benzodiazepine hypnotics (zolpidem, zopiclone) had similar profiles. Conclusion This pilot study suggests that postmarketing information on hypnotic drug use obtained from drug addicts entering treatment produces data consistent with other measures of abuse liability. The data suggest that the risk of misuse of newer non‐benzodiazepine hypnotics may be less than that of benzodiazepine drugs, and similar to that of sedating antidepressants. The new methodology may serve to clarify or validate premarketing abuse liability data, and may help to inform the regulatory process and physician practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sleep, sleepiness, sleep disorders and alcohol use and abuse
Roehrs, T., & Roth, T. (2001) · Sleep Medicine Reviews · doi:10.1053/smrv.2001.0162 · Cited by 328
Griffiths, R. R., Sannerud, C. A., Ator, N. A., & Brady, J. V. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11429-8 · Cited by 112
Research works printed but not linked: 21
- Aronson M. D., 1986, A case of trazodone‐induced ventricular tachycardia, Journal of Clinical Psychiatry, 47, 388
- Babor T. F., 1990, Validity of self‐reports in applied research on addictive behaviors: fact or fiction?, Behavioral Assessment, 12, 5
- 10.1111/j.1369-1600.2000.tb00215.x · doi:10.1111/j.1369-1600.2000.tb00215.x
- 10.1111/j.1360-0443.1986.tb00299.x · DOI · Paper page
- Evans S. M., 1990, Zolpidem and triazolam in humans. Behavioral and subjective effects and abuse liability, Journal of Pharmacology and Experimental Therapeutics, 255, 1246
- Griffiths R. R., 1987, Psychopharmacology: the Third Generation of Progress, 1535
- Griffiths R. R., 1990, Relative abuse liability of different benzodiazepines in drug abusers, Journal of Clinical Pharmacology, 10, 237
- 10.1016/0376-8716(93)90090-D · DOI
- 10.1176/ajp.140.6.796 · DOI
- 10.1016/S0376-8716(02)00107-2 · doi:10.1016/s0376-8716(02)00107-2
- 10.1176/appi.ajp.157.6.1022 · DOI
- Mendelson W. B., 2003, Sleep Medicine Reviews
- 10.1176/ajp.141.11.1472 · DOI
- 10.1016/S0278-5846(01)00262-7 · DOI
- 10.1016/0376-8716(81)90061-2 · DOI
- 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X · doi:10.1002/(sici)1099-1077(199804)13:3<191::aid-hup972>3.0.co;2-x
- 10.1093/sleep/22.3.371 · DOI · Paper page
- Woods J. H., 1998, Problems and opportunities in regulation of benzodiazepines, Journal of Clinical Pharmacology, 38, 773, 10.1002/j.1552-4604.1998.tb00009.x · DOI
- Woods J. H., 1987, Abuse liability of benzodiazepines, Pharmacology Reviews, 39, 251
- 10.1007/BF02245824 · DOI · Paper page
- 10.1016/S0006-3223(99)00176-6 · DOI
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia
Roth, T., Seiden, D., Sainati, S., Wang-Weigand, S., Zhang, J., & Zee, P. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.01.003 · Cited by 265
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
“About 80% of zopiclone users had obtained the drug through a prescription, but 42% reported having purchased it on the streets (Jaffe et al., 2004).”
Usage of benzodiazepines: A review
Donoghue, J., & Lader, M. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651500903447810 · Cited by 156
“As a separate but related issue, the relative abuse potential of sedative and hypnotic drugs is more diffi cult to establish [7].”
Background
Metadata
- Authors
- Jaffe, J. H., Bloor, R., Crome, I., Carr, M., Alam, F., Simmons, A., & Meyer, R. E.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2004-02
- Volume
- 99
- Issue
- 2
- Pages
- 165-173
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2067970495
- Cited by
- 67
- References
- 2
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A postmarketing study of relative abuse liability of hypnotic sedative drugs. https://app.cochat.ai/papers/10.1111/j.1360-0443.2003.00631.x
- The paper
- Jaffe, J. H., Bloor, R., Crome, I., Carr, M., Alam, F., Simmons, A., & Meyer, R. E. (2004). A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction. https://doi.org/10.1111/j.1360-0443.2003.00631.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.